D.E. Shaw & Co’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-282,154
| Closed | -$10.8M | – | 4647 |
|
|
2023
Q2 | $10.8M | Sell |
282,154
-37,552
| -12% | -$964K | 0.01% | 1275 |
|
|
2023
Q1 | $7.4M | Sell |
319,706
-40,079
| -11% | -$955K | 0.01% | 1616 |
|
|
2022
Q4 | $9.43M | Sell |
359,785
-119,742
| -25% | -$2.65M | 0.01% | 1490 |
|
|
2022
Q3 | $9.43M | Buy |
479,527
+225,945
| +89% | +$4.53M | 0.01% | 1405 |
|
|
2022
Q2 | $4.43M | Buy |
253,582
+191,135
| +306% | +$3M | 0.01% | 2275 |
|
|
2022
Q1 | $1.02M | Sell |
62,447
-65,655
| -51% | -$893K | ﹤0.01% | 3902 |
|
|
2021
Q4 | $2.09M | Buy |
128,102
+95,966
| +299% | +$1.37M | ﹤0.01% | 3310 |
|
|
2021
Q3 | $410K | Buy |
+32,136
| New | +$423K | ﹤0.01% | 4196 |
|
|
2021
Q1 | – | Sell |
-35,736
| Closed | -$567K | – | 4586 |
|
|
2020
Q4 | $567K | Buy |
35,736
+30,054
| +529% | +$453K | ﹤0.01% | 3329 |
|
|
2020
Q3 | $69K | Sell |
5,682
-16,533
| -74% | -$222K | ﹤0.01% | 3736 |
|
|
2020
Q2 | $257K | Sell |
22,215
-2,883
| -11% | -$39.7K | ﹤0.01% | 3683 |
|
|
2020
Q1 | $343K | Sell |
25,098
-56,805
| -69% | -$672K | ﹤0.01% | 3403 |
|
|
2019
Q4 | $484K | Buy |
81,903
+43,266
| +112% | +$235K | ﹤0.01% | 3414 |
|
|
2019
Q3 | $204K | Buy |
+38,637
| New | +$256K | ﹤0.01% | 3617 |
|
|
2019
Q2 | – | Sell |
-17,407
| Closed | -$346K | – | 3940 |
|
|
2019
Q1 | $346K | Buy |
17,407
+9,330
| +116% | +$163K | ﹤0.01% | 3162 |
|
|
2018
Q4 | $107K | Buy |
+8,077
| New | +$161K | ﹤0.01% | 3635 |
|
|
2016
Q1 | – | Sell |
-3,890
| Closed | -$547K | – | 3863 |
|
|
2015
Q4 | $547K | Buy |
+3,890
| New | +$528K | ﹤0.01% | 3033 |
|
D.E. Shaw & Co's KDNY Position: Q3 2023 in Review
D.E. Shaw & Co sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2023, closing a stake of 282,154 shares — an estimated $10.8M sold.
D.E. Shaw & Co first reported a position in KDNY in Q4 2015 and held it in 17 quarters. The position peaked at $10.8M in Q2 2023. 2 funds tracked by Wall St. Rank hold KDNY as of Q3 2023.
- D.E. Shaw & Co reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
- D.E. Shaw & Co sold 282,154 Chinook Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $10.8M.
- D.E. Shaw & Co first reported a position in Chinook Therapeutics, Inc. Common Stock in Q4 2015 and held it in 17 quarters.
- D.E. Shaw & Co's Chinook Therapeutics, Inc. Common Stock position peaked at $10.8M in Q2 2023.
- 2 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2023.
Based on D.E. Shaw & Co's 13F filing for Q3 2023, filed 14 Nov 2023.